Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Real-world analysis of treatment patterns and outcomes in older patients with Acute Myeloid Leukemia (AML) in the US community oncology setting

View Full Paper
Ask AI
Bookmark
Share

Authors

HEHoward EngleJEJanet L. Espirito

Discussion

Loading...

Member takes

Overview

Retrospective analysis reports treatment outcomes for older AML patients with venetoclax and hypomethylating agents, indicating high adoption of non-intensive therapies.

Key Points

  • Median overall survival for older AML patients was 11.0 months, with notable variance based on age at diagnosis.
  • Thirty percent of patients received venetoclax combined with hypomethylating agents after its 2020 FDA approval.
  • Observational analysis covered 4.5 years post-venetoclax approval across various age groups.
  • Findings highlight the importance of continued research on treatment patterns to enhance aging AML patient's quality of life.

Cite This Study

Engle et al. (2025) studied this question.

synapsesocial.com/papers/69362f514fa91c937236d9dehttps://doi.org/10.1182/blood-2025-5190
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Treatment intensity in older adults with AML: Impact of age and induction regimen on remission and survival outcomes2025
  2. 2Real-world outcomes of venetoclax-based therapy vs intensive chemotherapy in older adults with newly diagnosed Acute Myeloid Leukemia2025
  3. 3Contemporary outcomes of octa‐nonagenarians with newly diagnosed acute myeloid leukemia2025 · 4 citations
  4. 4A multicenter real-world study on response and survival in older patients with acute myeloid leukemia treated with intensive chemotherapy versus VEN/HMA by 2022 and 2024 ELN risk stratifications: An analysis from the MARROW consortium2025
  5. 5Venetoclax plus hypomethylating agent as first- and second-line treatment in patients with AML: A single-center experience2025